MedTrace Logo

Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy

NCT01865565 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2018-08-09

No results posted yet for this study

Summary

Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract. The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy from primary GIST. This is a prospective, multicenter, open, observational study in evaluation of safety and efficacy of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis. The study will include an up to 28-day screening period, followed by receiving imatinib mesylate (400 mg/day) for at least 6-12 months and followed up for 3 years after surgery.

Conditions

  • Gastrointestinal Stromal Tumor

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chun-Nan Yeh, MD · Chang Gung Memorial Hospital, Linkou, Taiwan.

  • Jen-Shi Chen, MD. · Chang Gung Memorial Hospital, Linkou, Taiwan.

  • Yen-Yang Chen, MD. · Chang Gung Memorial Hospital, Kaoshung, Taiwan.

  • Kun-Chun Chiang, MD. · Chang Gung Memorial Hospital, Keelung, Taiwan.

  • Liang-Mou Kuo, MD. · Chang Gung Memorial Hospital, Cha-Yi, Taiwan.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01865565 on ClinicalTrials.gov